Abnormal peripheral chemokine profile in Huntington's disease
about
The choreography of neuroinflammation in Huntington's diseaseSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemLaquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's diseaseNeuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesHuntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s diseaseMutant huntingtin impairs immune cell migration in Huntington disease.Age-associated chromatin relaxation is enhanced in Huntington's disease mice.The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder.Characterisation of immune cell function in fragment and full-length Huntington's disease mouse modelsThe role of the immune system in triplet repeat expansion diseasesMutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's diseaseBone marrow transplantation confers modest benefits in mouse models of Huntington's disease.Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.RNA pathogenesis via Toll-like receptor-activated inflammation in expanded repeat neurodegenerative diseases.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.JAK/STAT Signalling in Huntington's Disease Immune Cells.RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.Peripheral inflammation in neurodegeneration.Polyphenols: multipotent therapeutic agents in neurodegenerative diseases.The role of the immune system in Huntington's disease.Prospects for neuroprotective therapies in prodromal Huntington's disease.Innate immune activation in neurodegenerative disease.Challenges of Huntington's disease and quest for therapeutic biomarkers.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease.Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model.Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.A Novel Role for Lymphotactin (XCL1) Signaling in the Nervous System: XCL1 Acts via its Receptor XCR1 to Increase Trigeminal Neuronal Excitability.Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease
P2860
Q26828403-3E2D9180-87E7-4617-A1E1-A568757C6FD8Q26999386-D2EC7F58-0447-404A-B734-EC74E87EA26DQ27316866-CAF7CE26-CDC9-4D4A-8EB5-13DF6557C813Q27334472-B398CFAC-C191-4BAC-85B0-F378B58DA90DQ28072237-889467E8-450C-4167-B75E-49BE8CDF5308Q29248581-EEF1EDE9-9D45-4451-AEF7-FD7D4C298C04Q30530945-760A2369-79BC-4DC7-8EE9-087226A51A04Q33563614-602B2CE9-115B-424B-B801-36D7219F91CFQ33707686-3F979E00-F826-4440-940C-713BC2EEF201Q34674235-672C759A-FB3D-428F-B0A0-A543628C666DQ35271805-F1888AF0-255E-44E7-8A9A-796F5CEC642AQ35830504-3ABC788A-E5B7-4D1B-97B6-48C6BA012A50Q36142398-AE469ECD-7DB2-42C0-B194-81D618204285Q36608360-34806F3E-AF65-424B-BC88-C3DF84EEEBE6Q37120339-5D9E33A9-9537-4B36-8AF4-B21D788B078EQ37148589-5E71EE70-7223-47CE-999A-ACDD0B5C81B4Q37169655-0957C202-66BF-47DC-A1E1-31331F51D7F6Q37410973-A2F8250B-90DE-4E54-B6C7-42DDB0D105D5Q37530090-C23C4698-7E5C-4B91-A23F-0B6E0B157E3BQ37697482-69910FD3-A69D-4E44-B3DD-F6BC3B38BFE4Q38094970-305304B2-5F62-4595-B264-67773CB93A5EQ38120532-9B73D48D-3E04-44E8-BCAE-443218D0AAF8Q38129870-86F86D13-6C21-42C5-B768-1ED85927E02BQ38191477-11310190-10CD-4FF3-B1FB-655C9B805F49Q38223011-11E09292-FF67-4C88-B0B9-B864100526BBQ38257697-B1B15E1D-6AE6-48B6-B059-A9F66D3D44F0Q39035495-976E6892-7710-4CAB-A7DB-F519D470E75DQ39375357-291B3F6C-A6BC-4A3B-A04F-9C02ED8E97E5Q41898391-7AC63A75-9ED9-45BE-96D1-06D2D4D0D5AEQ42364364-FE74A218-2969-4F36-B0CD-4D8FA5B6FE09Q42918972-06B8ADD2-D2C2-4E70-ADA8-A27BBB75F720Q45305684-164C4A28-6AE9-445F-887C-8EEC57CA4E03Q47807749-9A355D80-2C32-438F-8782-0BB847884375Q52626921-101CEFA1-6E17-4281-8E85-A1A12D7941F2Q52663590-E47E6829-F2FD-4FB8-8053-FBCC4CC051F8Q57877015-B2C1356C-4644-4098-8C73-5A7D92EBD307
P2860
Abnormal peripheral chemokine profile in Huntington's disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Abnormal peripheral chemokine profile in Huntington's disease
@ast
Abnormal peripheral chemokine profile in Huntington's disease
@en
type
label
Abnormal peripheral chemokine profile in Huntington's disease
@ast
Abnormal peripheral chemokine profile in Huntington's disease
@en
prefLabel
Abnormal peripheral chemokine profile in Huntington's disease
@ast
Abnormal peripheral chemokine profile in Huntington's disease
@en
P2093
P2860
P50
P356
P1433
P1476
Abnormal peripheral chemokine profile in Huntington's disease
@en
P2093
Anna Magnusson
Maria Björkqvist
Ulrika Krus
P2860
P304
P356
10.1371/CURRENTS.RRN1231
P577
2011-04-13T00:00:00Z